New technologies and adaptations of existing technologies can improve platform processes.
Paul Mensah, PhD
Advertisement
Paul Mensah, PhD, is an associate research fellow, at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
Articles by Paul Mensah, PhD
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Advertisement
Latest Updated Articles
Advances in Monoclonal Antibody PurificationPublished: March 2nd 2010 | Updated:
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: October 2nd 2009 | Updated:
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
